JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M703919200 on September 7, 2007

J. Biol. Chem., Vol. 282, Issue 46, 33507-33514, November 16, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/46/33507    most recent
M703919200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanayasu-Toyoda, T.
Right arrow Articles by Yamaguchi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanayasu-Toyoda, T.
Right arrow Articles by Yamaguchi, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A New Role of Thrombopoietin Enhancing ex Vivo Expansion of Endothelial Precursor Cells Derived from AC133-positive Cells*

Toshie Kanayasu-Toyoda{ddagger}, Akiko Ishii-Watabe{ddagger}, Takayoshi Suzuki§, Tadashi Oshizawa§, and Teruhide Yamaguchi{ddagger}1

From the Divisions of {ddagger}Biological Chemistry and Biologicals, and §Cellular and Gene Therapy Products, National Institute of Health Sciences, Kamiyoga 1-18-1, Setagayaku, Tokyo 158-8501, Japan

We previously reported that CD31bright cells, which were sorted from cultured AC133+ cells of adult peripheral blood cells, differentiated more efficiently into endothelial cells than CD31+ cells or CD31- cells, suggesting that CD31bright cells may be endothelial precursor cells. In this study, we found that CD31bright cells have a strong ability to release cytokines. The mixture of vascular endothelial growth factor (VEGF), thrombopoietin (TPO), and stem cell factor stimulated ex vivo expansion of the total cell number from cultured AC133+ cells of adult peripheral blood cells and cord blood cells, resulting in incrementation of the adhesion cells, in which endothelial nitric oxide synthase and kinase insert domain-containing receptor were positive. Moreover, the mixture of VEGF and TPO increased the CD31bright cell population when compared with VEGF alone or the mixture of VEGF and stem cell factor. These data suggest that TPO is an important growth factor that can promote endothelial precursor cells expansion ex vivo.


Received for publication, May 14, 2007 , and in revised form, September 5, 2007.

* This work was supported in part by a grant-in-aid for health and labor science research from the Japanese Ministry of Health, Labor, and Welfare, and in part by a grant-in-aid for Research on Health Sciences focusing on Drug Innovation from the Japan Health Sciences Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed. Tel.: 81-3-3700-9064; Fax: 81-3-3707-6950; E-mail: yamaguch{at}nihs.go.jp.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.